TxCell’s Ovasave for IBD Receives Fast Track Designation from US FDA

TxCell’s Ovasave for IBD Receives Fast Track Designation from US FDA
TxCell SA, a biotechnology company that specializes in developing novel, patient-centered immunotherapies that utilize regulatory T-cells to address severe chronic inflammatory and autoimmune diseases, has just announced the US Food and Drug Administration (FDA) has granted the company’s flagship product Ovasave Fast Track Designation. The drug, which was also approved as an Investigational New Drug, is an

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *